Enterprise Development Resources | Cleveland Business Broker | Ohio Business Broker | Cleveland, Ohio Business Intermediary | Elias Ladon

Listing Information

bio-technology for cancer therapeutics
Listing ID: CancerTherapeutics	Location: Northeast U.S.
Brief: Cancer Therapeutic Drug developer is seeking partner(s) who are capable of bringing up to $10 million to the partnership. The company was founded in the early nineties and is at the stage of presenting the experimental results of its pre-clinical technology to Top Pharmaceutical companies in late 2009 and early 2010. This is in accordance to industry practices during which the large pharmaceutical companies take over the technology and after further investment of their own they secure FDA approval. Obviously large pharmaceutical companies proceed at this phase after they see serious and compelling evidence (like this company is ready to offer to them at the up-coming meetings.) Given the particular circumstances of the pre-clinical R&D results of this company they expect to enter into a license agreement with 1 or 2 large pharmaceuticals companies around mid-2010. WHEN THIS HAPPENS THE COMPANY EXPECTS THAT THE NEW PARTNER(S) WOULD SEE PAYBACK OF THEIR INVESTMENT WITHIN A SHORT PERIOD OF TIME AND SUBSEQUENTLY REALIZE HIGH RETURNS IN LINE WITH RETURNS IN SUCCESSFUL BIOTECHNOLOGY VENTURES. TECHNOLOGY HIGHLIGHTS: In essence company's technology may be summarized as follows: Development of cancer therapies designed to selectively stop the proliferation of cancer cells by targeting the molecular alterations responsible for their malignant transformation while minimally affecting normal cells. The company's lead drug candidates, which were licensed from a leading Ivy League University in November 2007, are inhibitors of mRNA translation at the level of initiation, and abrogate growth of human cancer cell lines and xenografted human tumors in mice with high potency and minimal or no toxicity. NOTE: Enterprise Development Resources, Inc. is functioning as a finder. Further representations of the company's technology and business proposal will be made by the management of the company. ======================================= Enterprise Development Resources, Inc. is neither a Broker-Dealer nor a registered Investment Adviser. Where applicable, securities transactions are conducted by Reliance Worldwide Investments, LLC, member FINRA, MSRB, and SIPC.

Listed Price:

$10,000,000

Total Sales:

N/A

Seller's Discretionary Earnings:

N/A

Fixtures Furniture, & Equipment:

Real Estate:

Inventory:

Financing / Terms:

Up-front investment after term sheet presentation and agreement.

Business Information

Year Established:

1991

Number of Employees:

0 Full Time / 0 Part Time

Days and Hours of Operation:

Relocatable:

Franchise Information:

Not Applicable.

Facilities / Location:

Major meto area in the Northeast of the U.S.

Lease Information

Lease Expiration Date:

Option:

Monthly Rent:

Additional Information

Reason for Selling:

Funding operating and financing needs of this R&D business which is at the verge of licensing its pre-clinical technology to pharmaceutical companies.

Business Description:

Cancer Therapeutic Drug developer is seeking partner(s) who are capable of bringing up to $10 million to the partnership. The company was founded in the early nineties and is at the stage of presenting the experimental results of its pre-clinical technology to Top Pharmaceutical companies in late 2009 and early 2010. This is in accordance to industry practices during which the large pharmaceutical companies take over the technology and after further investment of their own they secure FDA approval. Obviously large pharmaceutical companies proceed at this phase after they see serious and compelling evidence (like this company is ready to offer to them at the up-coming meetings.) Given the particular circumstances of the pre-clinical R&D results of this company they expect to enter into a license agreement with 1 or 2 large pharmaceuticals companies around mid-2010. WHEN THIS HAPPENS THE COMPANY EXPECTS THAT THE NEW PARTNER(S) WOULD SEE PAYBACK OF THEIR INVESTMENT WITHIN A SHORT PERIOD OF TIME AND SUBSEQUENTLY REALIZE HIGH RETURNS IN LINE WITH RETURNS IN SUCCESSFUL BIOTECHNOLOGY VENTURES. TECHNOLOGY HIGHLIGHTS: In essence company's technology may be summarized as follows: Development of cancer therapies designed to selectively stop the proliferation of cancer cells by targeting the molecular alterations responsible for their malignant transformation while minimally affecting normal cells. The company's lead drug candidates, which were licensed from a leading Ivy League University in November 2007, are inhibitors of mRNA translation at the level of initiation, and abrogate growth of human cancer cell lines and xenografted human tumors in mice with high potency and minimal or no toxicity. NOTE: Enterprise Development Resources, Inc. is functioning as a finder. Further representations of the company's technology and business proposal will be made by the management of the company. ======================================= Enterprise Development Resources, Inc. is neither a Broker-Dealer nor a registered Investment Adviser. Where applicable, securities transactions are conducted by Reliance Worldwide Investments, LLC, member FINRA, MSRB, and SIPC.

Potential for Growth:

Very significant driven by the need of large pharmaceutical companies to roll-out patented technologies for cancer curing drugs.